EXPLEO SOLUTIONS LIMITED
EXPLEOSOL · General/Diversified · NSE
₹826
Current Market Price
Fair Value (DCF)
₹2,272
Margin of Safety
+175.3%
Updated 2d ago
YieldIQ Score
70/100
Piotroski F-Score
6/9
Economic Moat
Wide
Confidence
52%
ROE
—
Debt/Equity
0.03
WACC
11.1%
Market Cap
₹1,281 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
20.8%
Return on capital employed
EV / EBITDA
6.0×
Enterprise multiple
Debt / EBITDA
0.2×
Leverage vs earnings
Interest Coverage
42.9×
EBIT covers interest
Current Ratio
3.90×
Short-term liquidity
Asset Turnover
1.23×
Revenue per ₹ of assets
Revenue CAGR (3Y)
11.3%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹825.5
Bear case
₹1,254.13
MoS +34.2%
Base case
₹2,272.2
MoS +63.7%
Bull case
₹2,587.32
MoS +68.1%
Ratio Trends
EXPLEOSOL · last 9 annual periods
ROE
16.2%
ROCE
27.3%
Operating Margin
—
Debt / Equity
0.05×
PE
65.6×
EV / EBITDA
8.1×
Historical Financials
EXPLEOSOL · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹301 Cr | ₹405 Cr | ₹231 Cr | ₹255 Cr | ₹1025 Cr | +35.8% |
| EBITDA | — | ₹130 Cr | ₹216 Cr | ₹156 Cr | ₹182 Cr | +8.7% |
| EBIT | ₹69.5 Cr | ₹68.0 Cr | ₹39.8 Cr | ₹26.9 Cr | — | -21.1% |
| PAT | ₹50.4 Cr | ₹49.8 Cr | ₹29.1 Cr | ₹15.7 Cr | ₹103 Cr | +19.6% |
| EPS (diluted) | ₹49.20 | ₹48.60 | ₹18.73 | ₹10.12 | — | -32.7% |
| CFO | ₹66.4 Cr | ₹32.7 Cr | ₹23.1 Cr | ₹71.3 Cr | ₹179 Cr | +28.2% |
| CapEx | — | — | — | — | ₹-7.9 Cr | — |
| FCF | — | — | — | — | ₹172 Cr | +0.0% |
| Total Assets | — | ₹594 Cr | ₹730 Cr | ₹765 Cr | ₹831 Cr | +8.8% |
| Total Debt | — | — | ₹0.1 Cr | ₹0.0 Cr | ₹29.8 Cr | +342.1% |
| Shareholders' Equity | — | — | ₹530 Cr | ₹611 Cr | ₹636 Cr | +4.6% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
EXPLEOSOL vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| DSSL DYNACONS SYS & SOLN LTD | -7.0% | 45 | Fairly valued | 31.3% | — |
| ORIENTTECH ORIENTTECH | — | — | Pending | 15.3% | — |
| IVALUE IVALUE | — | — | Pending | 18.5% | — |
| SILVERTUC SILVER TOUCH TECHNO LTD | -73.9% | 35 | Data Limited | 16.6% | — |
| MCLOUD MCLOUD | — | — | Pending | 19.8% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for EXPLEOSOL in the last 10 years.
Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of EXPLEOSOL →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for EXPLEOSOL →
Compare
Head-to-head with peers
Compare EXPLEOSOL side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse EXPLEOSOLNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.